Burimamide
![]()  | |
![]()  | |
| Names | |
|---|---|
| IUPAC name
 1-[4-(1H-imidazol-5-yl)butyl]-3-methylthiourea 
 | |
| Identifiers | |
3D model (JSmol) 
 | 
|
| ChEMBL | |
| ChemSpider | |
| KEGG | |
PubChem CID 
 | 
|
| UNII | |
CompTox Dashboard (EPA) 
 | 
|
  | |
  | |
| Properties | |
| C9H16N4S | |
| Molar mass | 212.32 g/mol | 
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). 
Infobox references 
 | |
Burimamide is an antagonist at the H2 and H3 histamine receptors. At physiological pH, it is largely inactive as an H2 antagonist,[1] but its H3 affinity is 100x higher. It is a thiourea derivative.
Burimamide was first developed by scientists at Smith, Kline & French (SK&F; now GlaxoSmithKline) in their intent to develop a histamine antagonist for the treatment of peptic ulcers.[2] The discovery of burimamide ultimately led to the development of cimetidine (Tagamet).[2]
See also
References
- ^ Clayden, Jonathan; Greeves, Nick; Warren, Stuart; Wothers, Peter (2001). Organic Chemistry (1st ed.). Oxford University Press. p. 205. ISBN 978-0-19-850346-0.
 - ^ a b "Tagamet: Discovery of Histamine H2-receptor Antagonists". National Historic Chemical Landmarks. American Chemical Society. Archived from the original on December 9, 2012. Retrieved June 25, 2012.
 

